Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Fei Xu, Kaping Lee, Shusen Wang, Qianyi Lu, Jin Wei, Kuikui Jiang, Xin An, Wen Xia, Liye Wang, Ruoxi Hong, Jinquan Yu, Weijia Tang, Zhongyu Yuan, Jia Jia Huang, Shengfeng Li, Cong Xue, Xiwen Bi, Danyang Zhou, Yanxia Shi
Publikováno v:
Cancer Communications, Vol 41, Iss 2, Pp 171-182 (2021)
Cancer Communications
Cancer Communications
Background The introductions of anti‐ human epidermal growth factor receptor‐2 (HER2) agents have significantly improved the treatment outcome of patients with HER2‐positive breast cancer. BAT8001 is a novel antibody‐drug conjugate targeting
Autor:
Zhongyu Yuan, Quchang Ouyang, Fei Xu, Roujun Peng, Shusen Wang, Danmei Pang, Yanxia Shi, Wen Xia, Qiufan Zheng, Qianyi Lu
Publikováno v:
Oncologist
Lessons Learned Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression-free survival of 16.1 months in patients who achieved objective responses or disease control after first-line chemotherapy. Adverse ev
Autor:
Yanhong Su, Zhongyu Yuan, Xinyue Wang, Shusen Wang, Jia Jia Huang, Xiwen Bi, Wei Shi, Zhangzan Huang, Wen Xia, Yanxia Shi, JiBin Li
Publikováno v:
Oncologist
Lessons Learned Moxifloxacin plus continuation of the previous treatment of physician's choice shows promising efficacy in patients with metastatic breast cancer. The addition of moxifloxacin shows well-tolerated toxicities. Background Recent studies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb0713d6036a06cac11c17b6a6065c9b
https://europepmc.org/articles/PMC7543292/
https://europepmc.org/articles/PMC7543292/
Autor:
Qiufan Zheng, Qianyi Lu, Ruoxi Hong, Kaping Lee, Fei Xu, Shusen Wang, Zhongyu Yuan, Yanxia Shi, Yuan Li, Qinglian Zhai, Wen Xia, Kuikui Jiang
Publikováno v:
Cancer Communications
Background Real‐world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small‐sample or retrospective studies. This study was aimed to determine the effectivenes
Autor:
Zhongyu Yuan, Shusen Wang, Tao Qin, Qianyi Lu, Wen Xia, Qiufan Zheng, Fei Xu, Ge Qin, Ruoxi Hong, Yanxia Shi
Publikováno v:
Breast Cancer Research and Treatment. 160:197-209
Endocrine therapy is associated with improved disease-free survival (DFS) in hormone receptor-positive breast cancer, but it is also associated with many adverse events. The aim of this study was to clarify the association between endocrine treatment
Autor:
Jonathan Arias-Fuenzalida, Lehong Zhang, Xin An, Wen Xia, Ruoxi Hong, Yanhong Su, Yong-Yi Zhong, Roujun Peng, JiBin Li, Heng Huang, Jinxin Zhang, Jia Jia Huang, Li Cai, Anqin Zhang, Zhongyu Yuan, Shusen Wang, Xinyue Wang, Yongxiang Gao, Cong Xue, Joseph M. Unger, Fei Xu, Ying Lin, Wei Shi, Yanxia Shi
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients. Met
Autor:
Tao Qin, Yan Xia Shi, Xiaoyu Teng, Dong-Geng Liu, Bing Bai, Zhongyu Yuan, S. Wang, Roujun Peng, Yin-Duo Zeng
Publikováno v:
Current Oncology
Volume 20
Issue 4
Pages 1231-204
Volume 20
Issue 4
Pages 1231-204
Given the use of tamoxifen as standard treatment for hormone receptor&ndash
positive breast cancer, the use of toremifene as an adjuvant endocrine therapy has not been widely examined. The present retrospective study compared the efficacy and sa
positive breast cancer, the use of toremifene as an adjuvant endocrine therapy has not been widely examined. The present retrospective study compared the efficacy and sa
Autor:
Cong Xue, Roujun Peng, Qiufan Zheng, Ge Qin, Tao Qin, Zhongyu Yuan, Jia Jia Huang, Yanxia Shi, Xin An, Qianyi Lu, Ruoxi Hong, Wen Xia, Shusen Wang, Fei Xu
Publikováno v:
Journal of Clinical Oncology. 34:e12001-e12001
e12001Background: Endocrine therapy is associated with definite improvements in disease-free survival in hormone receptor-positive breast cancer, but also with many adverse events. We conducted a s...